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Abstract
We prospectively analyzed 34 clinical biopsy samples from 23
patients with a suspected invasive fungal infection by fungal culture,
histology and a panfungal PCR followed by sequencing. Results
were compared to the composite diagnosis according the
European Organization for Research and Treatment of Cancer
(EORTC) criteria. In 34 samples, culture, histology and panfungal
PCR were positive in 35%, 38% and 62%, respectively. On the
sample level the panfungal PCR revealed a sensitivity of 69% and a
specificity of 62.5% compared to proven IFI according post-
operative EORTC criteria. On patient level, the sensitivity of the
PCR approach was 100%, specificity 62.5%.
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Invasive fungal infections (IFIs) in immunocompromised
patients are difficult to diagnose. Prognosis is poor in case of
delayed initiation of appropriate antifungal treatment [1].
Fungal cultures from biopsies have a low sensitivity [2] and
positive histology does not allow identification of the fungal
species with certainty. DNA-based tests have been developed
to improve the diagnostic yield, but are mostly restricted to
Candida [3], Aspergillus species [4] or both genera [5].
To address the usefulness of a panfungal PCR assay, we
prospectively included patients aged  18 years hospitalized at
the University Hospital Basel, Switzerland, between April 2009
and April 2011 with the suspicion of an invasive fungal infection
and in whom a tissue biopsy was performed.
Clinical information was assessed by an infectious disease
specialist. Neutropenia was defined as a neutrophil count of
<500mm3. IFIs were defined according to the EORTC criteria
[6] before and after surgery.
All samples were reviewed by specialized pathologists.
Fungal cultures were done on all specimens. Panfungal PCR
followed by sequencing was performed using primers ITS5 and
ITS4 for amplification of ITS region 1 and 2 as described (for
details see Supplementary Data).
For the calculation of sensitivity and specificity and the
corresponding negative (NPV) and positive predictive values
TABLE 1. Patients characteristics
Variable
Patients
(n = 23)
Patient age, median years (range) 53 (29–74)
Male sex 13 (57)
Underlying disease
Acute lymphatic leukemia 1 (4)
Acute myeloic leukema 6 (26)
Aplasitc anemia 2 (9)
Chronic lymphatic leukemia 1 (4)
Chronic myeloic leukema 1 (4)
Melodisplastic disease 3 (13)
Multiple myeloma 2 (9)
Morbus Hodgkin 1 (4)
Othera 6 (26)
Neutropenia before surgeryb 9 (39)
Biopsy site
Lung 15 (65)
Liver 5 (22)
Bone 2 (9)
Skin 1 (4)
Antifungal therapy before surgery 17 (74)
Voriconazole 9
Caspofungin 2
Liposomal Amphotericin B 2
Posaconazole 2
Fluconazole 1
Combination of liposomal Amphotericin B and Caspofungin 1
Antifungal therapy after surgery 22 (96)
Change of antifungal therapy
From Voriconazole to
Caspofungin 2
Liposomal Amphotericin B 1
Posaconazole 1
Fluconazole 1
From liposomal Amphotericin B to Voriconazole 2
From Caspofungin to Voriconazole 1
Liposomal Amphotericin B 1
Antifungal therapy stopped 1
Data are no. (%) of patients, unless otherwise indicated.
achronic obstructive lung disease (2twopatients), lung carcinoma (three patients),
arthritis (one patient).
b<0.5 9 109 neutrophils/L for >10 days median duration 23 days (IQR 5–47 days).
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(PPV) the results of panfungal PCR were used in relation to the
postoperatively proven IFI by EORTC criteria in all patients.
In a total of 23 patients, 34 tissue samples were obtained.
The characteristics of all patients are summarized in Table 1.
The underlying disease in 17 out of 23 patients was a
haematological malignancy. All of these patients had received
antifungal treatment for a median duration of 26 days (IQR 1–
51days) before biopsies were taken. In non-hematological
patients, suspicion of fungal infection was based upon
radiological and clinical findings and antifungal therapy was
begun only after definitive diagnosis of IFI.
Table 2 shows microbiological and histopathological results,
the clinical and radiological findings and the EORTC criteria
before and after surgery.
The rate of positive results from culture, histology and
panfungal PCR performed on 34 samples was 35% (12/34), 38%
(13/34) and 62% (21/34), respectively. All 12 culture-positive
samples were confirmed by PCR. In eight (35%) patients with
culture-negative, histology-positive samples, species identifica-
tion could be obtained with panfungal PCR. In three patients,
only the panfungal PCR was positive and in five patients
biopsies remained negative with either method.
According to the EORTC criteria applied to the 17 patients
with haematological malignancy before surgery, three cases
(17.6%) were classified as probable and 13 cases (76%) as a
possible IFI. After operation, the number of proven IFIs
increased to nine (53%) without panfungal PCR and to 12
(71%) if the results of the panfungal PCR were included. In the
six patients without haematological disease, IFI could be
proven with all three methods in two patients, in three
patients culture and panfungal PCR were concordantly
positive, and in one patient culture remained negative and
diagnosis of IFI was based on histology and panfungal PCR. On
the sample level the panfungal PCR revealed a sensitivity of
69%, a specificity of 62.5%, a PPV of 85.7% and a NPV of 38.4%
compared to proven IFI according to postoperative EORTC
criteria without PCR. On the patient level the panfungal PCR
revealed a sensitivity of 100% with a PPV of 83% and NPV of
100%. The specificity was the same as on sample level.
After definitive diagnosis of IFI, the empirical antifungal
therapy had to be adjusted in 10 hematological patients [see
Table 1 for details]. In two patients adjustment of therapy was
based on PCR results only.
We could show in this prospective single-centre study that
integration of a panfungal PCR into the EORTC criteria
increases the rate of proven IFI from 65% to 78% in the
diagnosis of invasive fungal infections.
Fungal culture is considered the microbiological gold
standard for diagnosis of IFI. In our study the diagnostic yield
of culture on sample level was 35%, compared with 62% of the
panfungal PCR. A small number of prospective studies have
assessed the clinical utility of a panfungal PCR approach in
patients at risk of an invasive fungal disease [7–11]. Compared
with these studies our panfungal PCR had a comparable
sensitivity, the specificity was lower and the PPV in the range
of previously published data [7,9]. Reasons for differences in
specificity might be the choice of ‘goldstandard’ for compar-
ison: most studies calculated sensitivity, specificity, PPV and
NPV of their panfungal PCR approach using all three EORTC
categories (proven, probable and possible) [7] or two of these
(proven and probable) IFI together [9,10]. The EORTC criteria
for IFI have been developed in consideration of the difficulties
in establishing a definitive diagnosis of IFI. As only proven IFI
represents a robust diagnosis, and many cases of possible and
probable IFI may be due to non-fungal causes, sensitivity and
specificity can be calculated reliably only for proven IFIs. In our
study, we therefore limited the statistical calculation to proven
IFI.
On the sample level, the sensitivity of 69% and a specificity
of 62.5% might seem low, and could be due to the limited
number of biopsies taken in most patients. Higher number of
samples lead to an improved sensitivity be it for culture,
histopathology or PCR and is probably the consequence of a
large necrosis area not containing fungal elements.
Furthermore, also small improvements in diagnosis of an IFI
with an exact fungal identification can have tremendous effect
on treatment, which usually is prescribed for several months.
To conclude, these preliminary results support the com-
plementary use of the panfungal PCR approach applied on
tissue specimens in combination with conventional laboratory
test methods. It allows a rapid detection and identification of
the fungal agent to the species level, particularly in culture-
negative specimens in patients with high clinical and/or
radiological suspicion of IFI.
Standardization and employment of panfungal PCR assays
need to be examined in carefully designed clinical studies with
larger sample sizes.
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